Web--Nektar Therapeutics announced today that it has appointed Brian Kotzin, MD as Interim Chief Medical Officer, Head of Development effective immediately. WebJan 5, 2024 · Brian Kotzin, MD added, "I am honored to expand my role at Nektar and work alongside Dr. Zalevsky. This is an exciting time for the company with multiple registrational studies underway in a range of tumor types for BEMPEG, a broadening clinical program for NKTR-358 in a number of auto-immune disorders, and an emerging …
Karin Eastham annonce qu
WebApr 11, 2024 · Le 6 avril 2024, Karin Eastham a informé le Conseil d'administration de Nektar Therapeutics qu'elle avait choisi de ne pas se représenter et qu'elle achèverait son mandat au Conseil à l'issue ... WebSAN FRANCISCO, May 3, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the appointment of Brian Kotzin, M.D. as Head of Clinical Development for Nektar's Immunology Program. In this newly-created role, Dr. Kotzin will lead clinical development for NKTR-358, a first-in … todays 49s teatime results
Nektar Appoints Dr. Brian Kotzin as Interim Chief Medical Officer …
WebJan 6, 2024 · Nektar Therapeutics, a biopharmaceutical company, announced that it has appointed Brian Kotzin, MD as Interim Chief Medical Officer, Head of Development … WebApr 26, 2024 · He will be succeeded by Dr. Brian Kotzin, Nektar's Head of Immunology, who brings over 30 years of drug development experience to the role and is an expert in the areas of immunology and inflammatory diseases. Dr. Kotzin had previously served as Nektar's interim CMO. John Northcott, Nektar's Chief Commercial Officer, who led the … WebJan 5, 2024 · SAN FRANCISCO, Jan. 5, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it has appointed Brian Kotzin, MD as Interim … todays 5 letter word